Since both the estrogen/ERα and PRL/PRLR signaling pathways are recognized as pathogenic mediators of pituitary adenoma, these aforementioned findings suggest that estrogen/ERα and PRL/PRLR signaling may be involved in the therapeutic resistance of prolactinomas. This evidence concerns the gene PRLR and pituitary gland adenoma.